{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:24:11Z","timestamp":1767338651843},"reference-count":9,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.clinthera.2011.07.006","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T18:58:40Z","timestamp":1312311520000},"page":"1077-1080","source":"Crossref","is-referenced-by-count":10,"title":["Hepatic Drug Interaction Between Tacrolimus and Lansoprazole in a Bone Marrow Transplant Patient Receiving Voriconazole and Harboring CYP2C19 and CYP3A5 Heterozygous Mutations"],"prefix":"10.1016","volume":"33","author":[{"given":"Takuya","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Monma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.07.006_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2133\/dmpk.23.134","article-title":"Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5","volume":"23","author":"Hosohata","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.07.006_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/bdd.544","article-title":"Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients","volume":"28","author":"Miura","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.clinthera.2011.07.006_bib3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1345\/aph.1D366","article-title":"Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism","volume":"38","author":"Takahashi","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2011.07.006_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.07.006_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","article-title":"Clinical pharmacokinetics of voriconazole","volume":"27","author":"Leveque","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2011.07.006_bib6","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.46.9.3091-3093.2002","article-title":"Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes","volume":"46","author":"Venkataramanan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.07.006_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/bmt.2009.38","article-title":"Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients","volume":"44","author":"Mori","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2011.07.006_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2011.07.006_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.108.025833","article-title":"Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients","volume":"37","author":"Hosohata","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811004917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811004917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:56:26Z","timestamp":1543625786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811004917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0149291811004917"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.07.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}